Vor Historical Cash Flow
| VOR Stock | USD 0.87 0.02 2.25% |
Analysis of Vor Biopharma cash flow over time is an excellent tool to project Vor Biopharma future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Net Borrowings of 2 M or Stock Based Compensation of 14 M as it is a great indicator of Vor Biopharma ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Vor Biopharma latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Vor Biopharma is a good buy for the upcoming year.
Vor |
About Vor Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Vor balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Vor's non-liquid assets can be easily converted into cash.
Vor Biopharma Cash Flow Chart
Add Fundamental
Net Borrowings
The difference between the amount of new debt a company has taken on and the amount of debt it has paid off during a given period.Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Most accounts from Vor Biopharma's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Vor Biopharma current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vor Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. To learn how to invest in Vor Stock, please use our How to Invest in Vor Biopharma guide.At this time, Vor Biopharma's Stock Based Compensation is relatively stable compared to the past year. As of 12/25/2024, Change In Working Capital is likely to grow to about 682.5 K, though Change In Cash is likely to grow to (25 M).
| 2023 | 2024 (projected) | Stock Based Compensation | 13.4M | 14.0M | Net Borrowings | 2.2M | 2.0M |
Vor Biopharma cash flow statement Correlations
Click cells to compare fundamentals
Vor Biopharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Vor Biopharma cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 7.1M | 42.1M | 72.1M | (62.1M) | (26.3M) | (25.0M) | |
| Stock Based Compensation | 172K | 1.3M | 4.3M | 10.7M | 13.4M | 14.0M | |
| Free Cash Flow | (10.6M) | (40.5M) | (73.0M) | (93.6M) | (101.4M) | (96.3M) | |
| Change In Working Capital | 145K | 4.3M | (9.2M) | (12.7M) | 650K | 682.5K | |
| Begin Period Cash Flow | 929K | 8.0M | 50.1M | 122.2M | 60.1M | 44.5M | |
| Other Cashflows From Financing Activities | 17.7K | 82.5M | 43.7M | 1.2M | (1.6M) | (1.6M) | |
| Depreciation | 91K | 605K | 1.4M | 2.5M | 3.5M | 3.7M | |
| Other Non Cash Items | 608K | 782K | 3.2M | 6.4M | 67K | 63.7K | |
| Total Cash From Operating Activities | (9.9M) | (36.3M) | (69.1M) | (85.1M) | (100.3M) | (95.3M) | |
| Change To Operating Activities | (1.1M) | (1.5M) | (9.6M) | (13.8M) | (12.4M) | (11.8M) | |
| Issuance Of Capital Stock | 17.7M | 82.3M | 234.6M | 116.0M | 116.2M | 103.9M | |
| Net Income | (10.8M) | (43.3M) | (68.9M) | (92.1M) | (117.9M) | (112.0M) | |
| Total Cash From Financing Activities | 17.7M | 82.5M | 232.9M | 117.1M | 2.9M | 2.8M | |
| End Period Cash Flow | 8.0M | 50.1M | 122.2M | 60.1M | 33.8M | 50.4M | |
| Change To Netincome | 748K | 2.1M | 4.5M | 10.7M | 12.3M | 12.9M | |
| Change To Liabilities | 1.2M | 5.8M | 405K | 1.1M | 1.3M | 1.9M |
Pair Trading with Vor Biopharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Vor Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Vor Biopharma will appreciate offsetting losses from the drop in the long position's value.Moving against Vor Stock
| 0.7 | VALN | Valneva SE ADR | PairCorr |
| 0.66 | DTIL | Precision BioSciences | PairCorr |
| 0.63 | DOMH | Dominari Holdings | PairCorr |
| 0.63 | DRRX | Durect | PairCorr |
| 0.63 | VIGL | Vigil Neuroscience | PairCorr |
The ability to find closely correlated positions to Vor Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Vor Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Vor Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Vor Biopharma to buy it.
The correlation of Vor Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Vor Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Vor Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Vor Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Vor Stock Analysis
When running Vor Biopharma's price analysis, check to measure Vor Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vor Biopharma is operating at the current time. Most of Vor Biopharma's value examination focuses on studying past and present price action to predict the probability of Vor Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vor Biopharma's price. Additionally, you may evaluate how the addition of Vor Biopharma to your portfolios can decrease your overall portfolio volatility.